Infertility is a significant public health concern in the United States. As such, utilization of infertility services, including pharmacotherapeutic treatments, is prevalent, and the role of the pharmacist as part of the health care team is essential. Pharmacists can assist patients by providing education on infertility causes, risk factor mitigation, referrals, nonpharmacologic and pharmacologic management options, navigation of the prescription process, and resource availability for the significant financial burden accompanying infertility treatment. In-depth pharmacotherapeutic information may not be readily available to pharmacists dispensing and counseling on these medications, and infertility management regimens are often varied and complicated requiring more in-depth counseling on use and administration. Given the complexity of infertility management, pharmacists are a valuable patient support and education resource. This article provides an in-depth review of infertility management strategies, both nonpharmacologic and pharmacologic.
Zegers-HochschildFAdamsonGDDyerS. The international glossary on infertility and fertility care, 2017. Fertil Steril. 2017;108(3):393–406.
2.
ChandraACopenCEStephenEH. Infertility and impaired fecundity in the United States, 1982-2010: data from the national survey of family growth. Natl Health Stat Rep. 2013;(67):1–18.
3.
StephenEHCandraA. Declining estimates of infertility in the United States: 1982-2002. Fertil Steril. 2006;86(3):516–523.
4.
LindsayTJVitrikasKR. Evaluation and treatment of infertility. Am Fam Physician. 2015;91(5):308–314.
5.
ChandraACopenSEStephenEH. Infertility services use in the United States: data from the National Survey of Family Growth, 1982-2010. Natl Health Stat Rep. 2014;(73):1–21.
6.
National Institute for Health and Care Excellence. Fertility: Assessment and Treatment for People with Fertility Problems. NICE; 2013:CG156. Accessed June 12, 2019. http://www.nice.org.uk/CG156
7.
SmithCGrimmMSchwegelM. Treatment of infertility in women. J Am Pharm Assoc. 2012;52(4):e27–e42.
8.
BroekmansFJKnauffEAValkenburgO, et al.PCOS according to the Rotterdam consensus criteria: change in the prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–1217.
9.
MarshburnPB. Counseling and diagnostic evaluation for the infertile couple. Obstet Gynecol Clin N Am. 2015;42(1):1–14.
10.
Practice Committee of American Society of Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44–e50.
11.
FerrarettiAPGianaroliL. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision?Hum Reprod. 2014;29(9):1842–1845.
12.
MaheshwariAHamiltonMBhattacharyaS. Effect of female age on the diagnostic categories of infertility. Hum Reprod. 2008;23(3):538–542.
13.
AndersonKNiesenblatVNormanR. Lifestyle factors in people seeking infertility treatment: a review. Aust N Z J Obstet Gynaecol. 2010;50(1):8–20.
14.
KinneyAKlineJKellyA, et al.Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod. 2007;22(4):1175–1185.
15.
PeckJDLevitonACowanLD. A review of the epidemiologic evidence concerning the reproductive health effects of caffeine consumption: a 2000-2009 update. Food Chem Toxicol. 2010;48(10):2549–2576.
16.
Rich-EdwardsJWSpiegelmanDGarlandM, et al.Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002;13(2):184–190.
17.
PasqualiRGambineriA. Metabolic effects of obesity on reproduction. Reprod Biomed Online. 2006;12(5):542–551.
18.
MandersMMc LindonLSchulzeB, et al.Timed intercourse for couples trying to conceive. Cochrane Database Syst Rev. 2015;3(3):CD011345.
19.
EcochardRDuterqueOLeivaR, et al.Self-identification of the clinical fertile window and the ovulation period. Fertil Steril. 2015;103(5):1319–1325.
20.
JohnsonSMarriottLZinamanM. Can apps and calendar methods predict ovulation with accuracy?Curr Med Res Opin. 2018;34(9):1587–1594.
21.
BehreHMKuhlageJGassnerC, et al.Prediction of ovulation by urinary hormone measurements with the home use clear plan fertility monitor: comparison with transvaginal ultrasound scans and serum hormone measurements. Hum Reprod. 2000;15(12):2478–2482.
22.
RobinsonJEWakelinMEllisJE. Increased pregnancy rate with use of the Clears Blue Easy Fertility Monitor. Fertil Steril. 2007;87(2):329–334.
23.
RighartsADicksonNPParkinLGillettWR. Ovulation monitoring and fertility knowledge: their relationship to fertility experience in a cross-sectional study. Aust N Z J Obstet Gynaecol. 2017;57(4):412–419.
24.
DunsonDBBairdDDColomboB. Increased infertility with age in men and women. Obstet Gynecol. 2004;103:51–56.
25.
MutsaertsMAGroenHHuitingHG, et al.The influence of maternal and paternal factors on time to pregnancy—a Dutch population-based birth-control cohort study: the GECKO Drenthe Study. Hum Reprod. 2012;27(2):583–593.
26.
VaamondeDDa Silva-GrigolettoMEGarcia-MansoJM, et al.Response of semen parameters to three training modalities. Fertil Steril.2009;92(6):1941–1946.
27.
ChavarroJERich-EdwardsJWRosnerBA, et al.Diet and lifestyle in the prevention of ovulatory disorder infertility. Obstet Gynecol. 2007;110(5):1050–1068.
28.
US Department of Health and Human Services (USDHHS). Women and Smoking. A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Published 2001. Accessed June 12, 2019. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5112a4.htm
29.
RossiBVChangGBerryKF, et al.In vitro fertilization outcomes and alcohol consumption in at-risk drinkers: the effects of a randomized intervention. Am J Addict. 2013;22(5):481–485.
30.
ChenZJShiYSunY, et al.Fresh versus frozen embryos for infertility in the polycystic ovarian syndrome. N Engl J Med. 2016;375(6):523–533.
31.
ShiYSunYCuiH. Transfer of fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126–136.
32.
Centers for Disease Control and Prevention. Key findings: use of intracytoplasmic sperm injection (ICSI) in the United States. Published 2016. Accessed June 12, 2019. https://www.cdc.gov/art/key-findings/icsi.html
33.
Practice Committees of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technology. Intracytoplasmic sperm injection (ICS) for non-male factor infertility: a committee opinion. Fertil Steril. 2012;98(6):1395–1399.
34.
Practice Committees of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technology. Recommendations for gamete and embryo donation: a committee opinion. Fertil Steril.2013;99(1):47–62.
DabajaAASchlegelPN. Medical treatment of male infertility. Trans Androl Urol. 2014;3(1):9–16.
37.
Clomid [Package Insert]. Sanofi-Aventis; 2006.
38.
DiamondMPLegroRSCourifarisC, et al.Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med. 2015;373(13):1230–1240.
39.
Lexi-Drugs 4.4.0. Hudson, OH: Lexi-Comp. Accessed June 12, 2019.
40.
PavoneMEBulunSE. The use of aromatase inhibitors for ovulation induction and superovulation. J Clin Endocrinol Metab. 2013;98(5):1838–1844.
41.
LegroRSBrzyskiRGDiamondMP, et al.Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129.
42.
FranikSKremerJANelenWL, et al.Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;2:CD010287.
43.
WeissNSNahuisMBayramN, et al.Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev. 2015;9(1):CD010290.
44.
European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab. 2001;86:2607.
45.
FauserBCVan HeusdenAM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(3):71.
46.
WhiteDMPolsonDWKiddyD, et al.Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81(11):3821–3824.
47.
Van SantbrinkEJDonderwinkelPFvan DesselTJ, et al.Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod. 1995;10(5):1048–1053.
48.
ImaniBEijkemansMJFaessenGH, et al.Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril. 2002;77(1):83–90.
49.
WestergaardLWBossuytPMM, et al.Human menopausal gonadotropin versus recombinant follicle stimulating hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;(1):CD003973.
50.
Al-InanyHGAboulgharMAMansourRT, et al.Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecol Endocrinol. 2005;20(2):161–169.
51.
Al-InanyHGAbou-SettaAMAboulgharMA, et al.Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol. 2009;25(6):372–378.
52.
JeeBCSuhCSKimYB, et al.Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis. Gynecol Obstet Invest. 2010;70(2):132–137.
53.
SiristatidisCSGibreelABasiosG, et al.Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2015;11(5):CD006919.
54.
AlbuquerqueLETsoLOSaconatoH, et al.Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;31(1):CD002808.
55.
Al-InanyHGYoussefMAAyelekeRO, et al.Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4(5):CD001750.
56.
LudwigMDoodyKJDoodyKM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril. 2003;79(5):1051–1059.
57.
YoussefMAAbou-SettaAMLamWS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2016;4(5):CD003719.
58.
CastilloJCHumaidanPBernabeuR. Pharmaceutical options for triggering of final oocyte maturation in ART. Biomed Res Int. 2014;2014:580171. doi:10.1155/2014/580171
59.
Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634–1647.
60.
BassiounyYADakhlyDMRBayoumiYA, et al.Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? a randomized, controlled trial. Fertil Steril. 2016;105(3):697–702.
YanushpolskyEH. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015;33(2):118–127.
63.
The Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Reproductive Endocrinology and Infertility. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;90(4):S150–S153.
64.
The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(5):37–43.
Van EmpelIWAartsJWCohlenBJ, et al.Measuring patient-centeredness, the neglected outcome in fertility care: a random multicenter validation study. Hum Reprod. 2010;25(10):2516–2526.
67.
DuthieEACooperADavisJB, et al.A conceptual framework for patient-centered fertility treatment. Reprod Health. 2017;14(1):114.
68.
Practice Committee of the American Society for Reproductive Medicine. Revised minimum standards for practices offering assisted reproductive technologies: a committee opinion. Fertil Steril. 2014;102(3):682–686.
